Lurbinectedin drug study for young people with Ewing sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests lurbinectedin, a cancer medicine, by itself (no other drugs) in children and young adults whose Ewing sarcoma has come back or did not respond to prior treatment. It aims to see how safe the drug is and whether it can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your age is 2 to under 18 (Phase 1 Part 1) or 2 to 30 (Phase 1 Part 2/Phase 2).
- You have confirmed solid tumor Ewing sarcoma that is relapsed or refractory (not responding).
- You can do daily activities fairly well (Lansky/Karnofsky score at least 50%).
- Blood test and organ function results are strong enough for study treatment (liver, kidneys, bone marrow, and heart).
- You meet minimum blood counts and weight needs (platelets, neutrophils, hemoglobin if needed, and weight at least 15 kg).
- You have not had certain recent treatments or infections, and you can follow study visit and medication rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests lurbinectedin, a chemotherapy medicine, in children and young adults whose solid tumors have a specific “FET fusion” gene change. It may help shrink tumors that have come back or did not respond to prior treatment, depending on the exact fusion type.
This trial is testing a new drug called xaluritamig for children, teens, and adults with Ewing sarcoma that has come back or is not responding to treatment. The goal is to see if this drug can shrink the cancer or stop it from growing.
This trial tests new drugs for young people with Ewing sarcoma or similar sarcomas that have come back or not responded to standard treatment. The goal is to see if these drugs can shrink or control the cancer.
This trial tests an experimental drug, KC1036, for adolescents with advanced Ewing sarcoma that has not responded to other treatments. It aims to see if the drug can help shrink tumors or slow the cancer.
This Phase 2 trial studies naxitamab (a targeted antibody) in children and young adults whose Ewing sarcoma has come back or kept growing despite prior treatment. You may be eligible if the tumor shows a target called GD2 and if your heart, lungs, and past treatment recovery meet safety requirements.
This trial tests a combination of three drugs (liposomal irinotecan, temozolomide, and fluzoparib) for people with Ewing sarcoma that has spread or come back after first treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
Hear when a new Refractory Ewing Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.